Research

February 11, 2026

Vaccination cuts risk of COVID-19 respiratory failure or death by 80%

Researchers at Vanderbilt Health and around the country continue to evaluate the effectiveness of vaccines approved by the Food and Drug Administration to reduce the severity and lethality of respiratory infections caused by the ever-mutating SARS-CoV-2 virus.

February 11, 2026

Heart preservation technique increases pool of organs available for transplant

The technique, termed REUP (rapid recovery with extended ultraoxygenated preservation), avoids traditional methods that reanimate the heart within or outside the donor’s body.

February 9, 2026

AI finds patient-level statin barriers in clinical notes

A novel AI framework found documented intolerance to statins in 6.4% of all adult patients, contraindications in 0.7%, and statin deferral in 2.9%.

February 9, 2026

Vanderbilt research uncovers new clue to insulin resistance

The latest findings could lead to more targeted ways to increase insulin-stimulated glucose uptake by muscle and exercise tolerance.

Members of the Vanderbilt Health team are evaluating the efficacy of the immunomodulatory drug baricitinib for treating the persistent neurological and cardiopulmonary symptoms of long COVID. (photo by Donn Jones)
February 6, 2026

Vanderbilt Health to lead expanded multisite study of immunomodulation in long COVID

The public health burden of long COVID is estimated to be the largest seen from an emerging disease in the past century, yet there remain no effective interventions.

February 6, 2026

New analytical approach identifies novel risk genes for colorectal cancer

The study advances understanding of risk for colon and rectal cancers and points to targets for developing new treatments.